Summary of indirect comparisons to evaluate efficacy of baricitinib with targeted synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis

被引：0
|
作者：
Emery, P. [1 ]
Dudler , J. [2 ]
Smolen, J. [3 ]
Zerbini, C. [4 ]
Burmester, G. [5 ]
Fautrel, B. [6 ]
van de Laar, M. [7 ]
Fleischmann, R. [8 ]
Fakhouri, W. [9 ]
De Leonardis, F. [9 ]
Zhu, B. [9 ]
Kadziola, Z. [9 ]
De La Torre, I [9 ]
Perrier, C. [9 ]
Taylor, P. [10 ]
机构：
[1] Leeds MSK Biomed Chapel Allerton Hosp, Leeds, W Yorkshire, England
[2] HFR Fribourg Hop Cantonal, Fribourg, Switzerland
[3] Med Univ Vienna, Vienna, Austria
[4] Ctr Paulista Invest Sao Paulo Clin, Sao Paulo, Brazil
[5] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany
[6] Pierre & Marie Curie, Paris, France
[7] Arthritis Ctr Twente, Enschede, Netherlands
[8] Univ Texas SouthWestern Med Ctr, Dallas, TX USA
[9] Eli Lilly & Co, Indianapolis, IN USA
[10] Univ Oxford, Botnar Res, Headington, England
来源：
SWISS MEDICAL WEEKLY | 2019年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P 6
引用
收藏
页码：7S / 8S
页数：2
相关论文
共 50 条
  • [1] SUMMARY OF INDIRECT COMPARISON TO EVALUATE EFFICACY OF BARICITINIB WITH TARGETED SYNTHETIC AND BIOLOGIC DISEASE ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Emery, Paul
    Dudler, Jean
    Smolen, Josef
    Zerbini, Cristiano
    Burmester, Gerd
    Fautrel, Bruno
    van der Laar, Mart
    Fleischmann, Roy
    Fakhouri, Walid
    De Leonardis, Francesco
    Zhu, Baojin
    Kadziola, Zbigniew
    De La Torre, Inmaculada
    Perrier, Clementine
    Taylor, Peter C.
    RHEUMATOLOGY, 2019, 58
  • [2] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [3] Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis
    Sendaydiego, Xavier
    Gold, Laura S.
    Dubreuil, Maureen
    Andrews, James S.
    Reid, Pankti
    Liew, David F. L.
    Goulabchand, Radjiv
    Hughes, Grant C.
    Sparks, Jeffrey A.
    Jarvik, Jeffrey G.
    Singh, Siddharth
    Liew, Jean W.
    Singh, Namrata
    RHEUMATOLOGY, 2025,
  • [4] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Leung Cheuk Hong
    Liang Li
    Maria E. Suarez-Almazor
    Clinical Rheumatology, 2020, 39 : 787 - 794
  • [5] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Hong, Leung Cheuk
    Li, Liang
    Suarez-Almazor, Maria E.
    CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794
  • [6] Biologic and targeted synthetic disease-modifying anti-rheumatic drugs improve body composition in rheumatoid arthritis patients more than conventional synthetic disease-modifying anti-rheumatic drugs: Results from the PRESENT study
    Tada, Masahiro
    Matsumoto, Yoshinari
    Koike, Tatsuya
    Mamoto, Kenji
    Nakamura, Tomoyuki
    Anno, Shohei
    Iida, Takahiro
    Goto, Hitoshi
    Hidaka, Noriaki
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (10)
  • [7] Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
    Choy, Ernest H.
    RHEUMATOLOGY, 2019, 58 : 51 - 55
  • [8] Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis
    Whittle, Samuel L.
    Glennon, Vanessa
    Johnston, Renea, V
    Avery, Jodie C.
    Bell, J. Simon
    Brennan, Sue E.
    Fong, Christopher
    Hissaria, Pravin
    Horgan, Ben
    O'Neill, Sean
    Pisaniello, Huai Leng
    Trevena, Lyndal
    Whittaker, Glen A.
    Wluka, Anita
    Buchbinder, Rachelle
    INTERNAL MEDICINE JOURNAL, 2022, 52 (10) : 1799 - 1805
  • [9] USE OF BIOLOGIC OR TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AND THE RISK OF LYMPHOMA IN RHEUMATOID ARTHRITIS
    Singh, N.
    Peterson, A.
    Baraff, A.
    Bhatti, P.
    Gopal, A.
    Smith, N.
    Barton, J.
    Curtis, J.
    Li, C.
    Weiss, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1060 - 1061
  • [10] Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis
    Singh, Namrata
    Peterson, Alexander
    Baraff, Aaron
    Gopal, Ajay
    Smith, Nicholas
    Barton, Jennifer
    Curtis, Jeffrey
    Weiss, Noel
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2381 - 2382
12345